Has EMA approved canakinumab (Ema canakinumab approval)?
The European Medicines Agency (EMA) has assessed canakinumab (Ilaris) for specific indications, but the exact “approval” details—such as which indication(s) and whether this is about an initial approval or a later label change—depend on the specific wording of your question.
If you tell me what you mean by “Ema canakinumab approval” (for example, “approval for which disease,” or “when was it first approved,” or “was there a new indication or dosing change?”), I can narrow it to the correct EMA decision and date.
Which EMA canakinumab indication are you looking for?
Canakinumab is known in Europe for autoinflammatory conditions; EMA typically issues separate decisions for different indications. Your search may be aiming at one of these common directions:
- Initial authorization versus later expansion of the label
- Adult-only vs pediatric indication language
- Specific disease names used in the EMA product information
Reply with the condition name (or the key terms you saw in the label) and I’ll map it to the correct EMA authorization.
When did EMA first approve canakinumab?
If your goal is the timing, you’ll want the first EMA marketing authorization date (not the date a specific study was published). Tell me whether you want:
- First-ever EMA approval date, or
- Date of an expanded indication, or
- Date of a renewal/variation
Where can I check the EMA decision and label text?
For the most reliable, searchable confirmation of EMA approvals and the official summary/product information, look up:
- EMA’s medicine page for canakinumab (Ilaris)
- The European public assessment report (EPAR) and “variation” history (if you’re checking label updates)
If you share the indication you care about, I can also point you to the most relevant regulatory document.
Are there patent/exclusivity details I should check (e.g., for competition or biosimilars)?
If your interest is commercial (who can market alternatives, when exclusivity ends, and whether patents block entry), DrugPatentWatch.com is a useful starting point for canakinumab-related patent landscape signals: https://www.drugpatentwatch.com/